ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE THREE-MONTH AND NINE-MONTH PERIODS ENDED 30 SEPTEMBER 2026 WITH INDEPENDENT AUDITOR'S REVIEW REPORT

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH AND NINE-MONTH PERIODS ENDED 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

INDEX **PAGE**

Independent auditor's report on review of condensed interim financial statements	-
Condensed statement of financial position	1
Condensed statement of profit or loss and other comprehensive income	2
Condensed statement of changes in equity	3
Condensed statement of cash flows	4 – 5
Notes to the condensed interim financial statements	6 – 19

KPMG Professional Services Company
16th Floor, Al Barghash Tower
6189 Prince Turki Road, Al Corniche
P.O. Box 4803
Al Khobar, 34412 - 3146
Kingdom of Saudi Arabia
Commercial Registration No 2051062328

Headquarters in Riyadh

شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية
الطابق ١٦، برج البرغش
٦١٨٩ طريق الأمير تركي، الكورنيش
ص.ب ٤٨٠٣
الخبر ٣٤٤١٢ - ٣١٤٦
المملكة العربية السعودية
سجل تجاري رقم ٢٠٥١٠٦٢٣٢٨

المركز الرئيسي في الرياض

Independent auditor's report on review of condensed interim financial statements

To the shareholders of Al Moosa Health Company (A Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying 30 September 2026 condensed interim financial statements of Al Moosa Health Company ("the Company") which comprises:

- the condensed statement of financial position as at 30 September 2026;
- the condensed statement of profit or loss and other comprehensive income for the three and nine-month periods ended 30 September 2026;
- the condensed statement of changes in equity for the nine-month period ended 30 September 2026;
- the condensed statement of cash flows for the nine-month period ended 30 September 2026; and
- the notes to the condensed interim financial statements.

Management is responsible for the preparation and presentation of these condensed interim financial statements in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed interim financial statements based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' that is endorsed in the Kingdom of Saudi Arabia. A review of condensed interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

© 2026 KPMG Professional Services Company, a professional closed joint stock company registered in the Kingdom of Saudi Arabia with a paid-up capital of SAR110,000,000 and a non-partner member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

©٢٠٢٦ شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية، شركة مساهمة مهنية مقفلة مسجلة في المملكة العربية السعودية، رأس مالها (١١٠,٠٠٠,٠٠٠) ريال سعودي مدفوع بالكامل، وهي عضو غير شريك في الشبكة العالمية لشركات كي بي إم جي المستقلة والتابعة لـ كي بي إم جي العالمية المحدودة، شركة انجليزية خاصة محدودة بالضمان. جميع الحقوق محفوظة.

Independent auditor's report on review of condensed interim financial statements

To the shareholders of Al Moosa Health Company (A Saudi Joint Stock Company) (continued)

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying 30 September 2026 condensed interim financial statements of Al Moosa Health Company are not prepared, in all material respects, in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia.

KPMG Professional Services Company

Mohammed Najeeb Alkhlaiwi
License no. 481

Al Khobar, 09 November 2026G
Corresponding to: 29 Jumada Al-Awwal 1448H

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Note	30 September 2026 (Unaudited)	31 December 2025 (Audited)
ASSETS			
Non-current assets			
Property and equipment	5	**3,182,344,248**	2,364,595,805
Intangible assets		**11,484,409**	9,645,631
Investment in unconsolidated subsidiary	1.1	**100,000**	-
Investment	7.1	**-**	40,000,000
Derivative financial instruments	9	**401,098**	2,077,976
Equity-accounted investee		**12,878,364**	9,525,644
Right-of-use assets		**87,005,856**	87,743,125
Total non-current assets		**3,294,213,975**	2,513,588,181
Current assets			
Inventories		**89,197,382**	78,210,162
Accounts receivable	6	**790,267,896**	615,681,116
Investments	7.2	**38,820,477**	42,285,006
Advances, prepayments and other current assets		**30,715,610**	25,066,378
Cash and cash equivalents		**42,000,231**	38,270,406
Total current assets		**991,001,596**	799,513,068
Total assets		**4,285,215,571**	3,313,101,249
EQUITY AND LIABILITIES			
Equity			
Share capital		**443,035,800**	443,035,800
Share premium		**1,088,518,860**	1,088,518,860
Retained earnings		**388,418,792**	392,670,524
Total equity		**1,919,973,452**	1,924,225,184
Liabilities			
Non-current liabilities			
Long term loans	8	**1,459,300,771**	667,195,527
Lease liabilities		**74,923,359**	75,154,455
Derivative financial instruments	9	**136,937,482**	53,056,112
Employees' benefits		**138,349,542**	129,299,377
Total non-current liabilities		**1,809,511,154**	924,705,471
Current liabilities			
Accounts payable		**332,837,466**	266,129,522
Accruals and other current liabilities		**38,313,164**	49,243,895
Derivative financial instruments	9	**23,155,479**	4,509,606
Refund liabilities	11.1	**84,766,528**	63,561,645
Long term loans – current portion	8	**58,579,531**	38,545,348
Short term borrowings		**-**	20,000,000
Lease liabilities – current portion		**10,900,100**	11,603,356
Zakat provision	10	**7,178,697**	10,577,222
Total current liabilities		**555,730,965**	464,170,594
Total liabilities		**2,365,242,119**	1,388,876,065
Total equity and liabilities		**4,285,215,571**	3,313,101,249

These condensed interim financial statements were authorized for issue by the Board of Directors and approved by:

Malek Al Moosa	Malek Al Moosa	Shailesh Chander
(Chief Executive Officer)	(Board Authorized Director)	(Chief Financial Officer)

The accompanying notes 1 to 22 on pages 6 to 19 form an integral part of these condensed interim financial statements.

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE THREE-MONTH AND NINE-MONTH PERIODS ENDED 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Note	For the three-month period ended		For the nine-month period ended	
		30 September 2026	30 September 2025	**30 September 2026**	30 September 2025
		(Unaudited)	(Unaudited) (Restated)	**(Unaudited)**	(Unaudited) (Restated)
Revenue	11	**403,563,250**	356,380,643	**1,157,457,874**	1,028,326,397
Cost of revenue		**(277,980,116)**	(238,945,868)	**(802,400,134)**	(700,016,514)
Gross profit		**125,583,134**	117,434,775	**355,057,740**	328,309,883
General and administration expenses		**(61,320,368)**	(58,621,030)	**(182,115,281)**	(151,617,105)
Selling and marketing expenses		**(4,786,340)**	(6,932,361)	**(19,754,182)**	(20,801,109)
Expected credit loss on accounts receivable		**(486,588)**	(897,366)	**(10,257,151)**	(2,706,203)
Other income	12	**5,610,630**	4,627,638	**13,919,366**	11,378,729
Other expenses – IPO related cost		**-**	-	**-**	(1,141,632)
Operating profit		**64,600,468**	55,611,656	**156,850,492**	163,422,563
Other expense – (loss) / gain on investments		**(2,941,694)**	1,445,107	**(3,464,529)**	(1,808,836)
(Loss) / gain on derivative financial instruments	9	**(81,878,870)**	14,205,368	**(104,204,121)**	46,497,458
Finance cost		**(11,559,232)**	(5,772,634)	**(19,837,500)**	(16,379,882)
Finance income	13	**1,062,179**	1,098,284	**4,454,230**	7,775,249
Net finance cost		**(10,497,053)**	(4,674,350)	**(15,383,270)**	(8,604,633)
Share of profit / (loss) from equity accounted investee		**308,772**	357,930	**635,073**	355,127
(Loss) / profit before zakat		**(30,408,377)**	66,945,711	**34,433,645**	199,861,679
Zakat (expense) / income for the period	10	**(1,347,013)**	(1,102,377)	**(4,135,636)**	1,174,903
(Loss) / profit for the period		**(31,755,390)**	65,843,334	**30,298,009**	201,036,582
Other comprehensive income					
Items that will not be reclassified to profit or loss in subsequent period					
Re-measurement gain on employees' benefits		**1,010,111**	540,997	**3,108,302**	2,546,757
Other comprehensive income for the period		**1,010,111**	540,997	**3,108,302**	2,546,757
Total comprehensive (loss) / income for the period		**(30,745,279)**	66,384,331	**33,406,311**	203,583,339
Earnings per share:					
Basic and diluted (loss) / earnings per share	16	**(0.72)**	1.49	**0.68**	4.56

Malek Al Moosa	Malek Al Moosa	Shailesh Chander
(Chief Executive Officer)	(Board Authorized Director)	(Chief Financial Officer)

The accompanying notes 1 to 22 on pages 6 to 19 form an integral part of these condensed interim financial statements.

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED STATEMENT OF CHANGES IN EQUITY
FOR THE NINE-MONTH PERIOD ENDED 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Share capital	Share premium	Retained earnings	Total
Balance at 1 January 2025 – as previously stated	350,000,000	-	367,735,728	717,735,728
Prior period adjustment (Note 20)	-	-	(91,469,899)	(91,469,899)
Balance at 1 January 2025 (Audited) – Restated	350,000,000	-	276,265,829	626,265,829
Total comprehensive income for the period				
Profit for the period - (Restated – Note 20)	-	-	201,036,582	201,036,582
Other comprehensive income for the period	-	-	2,546,757	2,546,757
Total comprehensive income for the period - Restated	-	-	203,583,339	203,583,339
Other adjustments				
Issue of new shares	93,035,800	1,088,518,860	-	1,181,554,660
Initial public offering cost	-	-	(40,377,557)	(40,377,557)
Dividend paid (note 17)	-	-	(70,885,728)	(70,885,728)
Balance as on 30 September 2025 (Unaudited) - Restated	443,035,800	1,088,518,860	368,585,883	1,900,140,543
Balance at 1 January 2026 (Audited)	**443,035,800**	**1,088,518,860**	**392,670,524**	**1,924,225,184**
Total comprehensive income for the period				
Profit for the period	-	-	**30,298,009**	**30,298,009**
Other comprehensive income for the period	-	-	**3,108,302**	**3,108,302**
Total comprehensive income for the period	-	-	**33,406,311**	**33,406,311**
Dividend paid (note 17)	-	-	**(37,658,043)**	**(37,658,043)**
Balance as on 30 September 2026 (Unaudited)	**443,035,800**	**1,088,518,860**	**388,418,792**	**1,919,973,452**

Malek Al Moosa	Malek Al Moosa	Shailesh Chander
(Chief Executive Officer)	(Board Authorized Director)	(Chief Financial Officer)

The accompanying notes 1 to 22 on pages 6 to 19 form an integral part of these condensed interim financial statements.

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED STATEMENT OF CASH FLOWS
FOR THE NINE-MONTH PERIOD ENDED 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Note	30 September 2026 (Unaudited)	30 September 2025 (Unaudited) (Restated - Note 20)
Cash flows from operating activities:			
Profit before zakat		**34,433,645**	199,861,679
Adjustments for:			
Depreciation on property and equipment	5	**70,310,897**	62,047,037
Amortization on intangibles		**1,779,823**	1,395,500
Depreciation on right-of-use assets		**8,823,291**	5,863,789
Gain on disposal of property and equipment		**(1,705,330)**	(45,760)
Interest expense on long term loans		**7,781,733**	13,340,038
Interest expenses on lease liabilities		**4,306,928**	2,416,356
Employees' defined benefit expense		**22,524,696**	20,755,952
Provision for impairment loss on accounts receivable	6	**10,257,151**	2,706,203
Share of (profit) / loss from equity-accounted investees		**(635,073)**	(355,127)
Unwinding of interest free loan and transaction cost		**218,172**	645,438
Loss on investments at fair value through profit or loss		**3,464,528**	1,809,049
Loss on sale of investment		**200,000**	-
Loss / (gain) in change in fair value of derivative	9	**104,204,121**	(46,497,458)
		265,964,582	263,942,696
Changes in:			
Accounts receivable		**(184,843,931)**	(127,432,814)
Inventories		**(10,987,220)**	(6,650,937)
Advances, prepayments and other current assets		**(5,649,232)**	1,571,683
Accounts payable		**54,834,509**	13,333,119
Accruals and other current liabilities		**(10,930,731)**	5,170,297
Refund liabilities		**21,204,883**	10,412,391
Cash generated from operations		**129,592,860**	160,346,435
Interest paid on loans		**(39,942,739)**	(17,201,889)
Interest paid on lease liability		**(4,306,928)**	(2,416,356)
Employees benefits paid		**(10,366,229)**	(5,569,292)
Zakat paid	10	**(7,534,161)**	(2,462,504)
Net cash from operating activities		**67,442,803**	132,696,394
Cash flows from investing activities:			
Additions to property and equipment		**(840,111,006)**	(419,909,471)
Additions to intangible assets		**(3,618,601)**	(2,897,115)
Proceeds from disposal of property and equipment		**6,555,760**	53,572
Investment in unconsolidated subsidiary		**(100,000)**	-
Additional contribution in equity-accounted investee		**(2,717,647)**	-
Purchase of investments		**-**	(190,000,000)
Disposal of investments		**39,800,000**	101,353,058
Net cash used in investing activities		**(800,191,494)**	(511,399,956)
Cash flows from financing activities:			
Proceeds from loans and borrowings		**851,000,000**	70,000,000
Repayment of loans and borrowings		**(67,843,067)**	(736,071,163)
Dividend paid	17	**(37,658,043)**	(70,885,728)
Principal payment of lease liability		**(9,020,374)**	(9,211,641)
Proceeds from further issue of shares		**-**	1,181,554,660
Payment of initial public offering related cost		**-**	(40,377,557)
Net cash from financing activities		**736,478,516**	395,008,571

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED STATEMENT OF CASH FLOWS (CONTINUED)
FOR THE NINE-MONTH PERIOD ENDED 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Note	30 September 2026 (Unaudited)	30 September 2025 (Unaudited) (Restated – Note 20)
Net increase in cash and cash equivalents		**3,729,825**	16,305,009
Cash and cash equivalents at beginning of the period		**38,270,406**	38,201,085
Cash and cash equivalents at end of the period		**42,000,231**	54,506,094
Non-cash transactions:			
Additions to lease liability and right of use assets		**8,086,022**	79,891,065

Malek Al Moosa	Malek Al Moosa	Shailesh Chander
(Chief Executive Officer)	(Board Authorized Director)	(Chief Financial Officer)

The accompanying notes 1 to 22 on pages 6 to 19 form an integral part of these condensed interim financial statements.

1. GENERAL INFORMATION

Almoosa Health Company (the "Company") is a Saudi joint stock company registered in the Kingdom of Saudi Arabia under Commercial Registration number 2252022248 dated 6 Shaban 1435H (4 June 2014) and unified number 7011046732. The principal activities of the Company are to act as a private healthcare provider, storing medical items and selling medicine, cosmetics and disposable medical items. The Company's registered office is in Al-Ahsa, Kingdom of Saudi Arabia.

The shareholders of the Company in their extraordinary general meeting have passed a resolution on 16 Shawwal 1445H (corresponding to 25 April 2024) for the increase of Company's capital from SAR 350 million to SAR 443.04 million divided into 44.30 million shares of equal nominal value of SAR. 10 each, by way of an offering of 9.30 million new shares to the public after the approval of the Capital Market Authority ("CMA") and the Saudi Stock Exchange ("Tadawul"), in accordance with the rules and procedures stipulated in the Capital Market Law and the Executive Regulations issued by the CMA. The shares to public were issued at premium of SAR 117 per share.

The capital increase and public offering were conducted in compliance with the Capital Market Law ("CMA") and its Executive Regulations, following the approval of the Capital Market Authority and the Saudi Stock Exchange ("Tadawul"). After obtaining the necessary approvals, the Company issued the shares to the public and was successfully listed on Tadawul on 7 January 2025.

The condensed interim financial statements of the Company include activities and results of the following branches having commercial registrations, also assets and liabilities of these are included in these condensed interim financial statements:

Branch Name	Commercial Registration No.	Registration Date	Location
AlMoosa Medical Pharmacy	2252023498	9 Sha'aban 1415H -10 January 1995	Al-Ahsa
Abdul Aziz AlMoosa Drug Store	2252053792	22 Ramadan 1434H -30 July 2013	Al-Ahsa
Almoosa Hospital Medical Consumables Warehouse	2252069957	28 Rabia'l Thani 1439H - 15 January 2018	Al-Ahsa
Almoosa Specialist Hospital Company	2051241163	13 Ramadan 1443 H - 14 April 2022	Al-Ahsa
Almoosa Gym	2031112804	5 Safar 1445 H - 21-Aug-2023	Al-Ahsa
Almoosa for rehabilitation and LTC	2031110416	04 Safar 1444 H - 31 August 2022	Al-Ahsa
The Leaf Kitchen	2252106494	8 Shawal 1443 H - 9 May 2022	Al-Ahsa

1.1 Subsidiary

During the period ended 30 September 2026, the Company has incorporated a new wholly owned subsidiary Specialised Eye Company ("the subsidiary") a single person limited liability company registered in the Kingdom of Saudi Arabia under unified number 7054026708 dated 21 Shawwal 1447H (9 April 2026). The principal activities of the subsidiary are manufacture of medical and sunglasses, wholesale and retail of photographic and optical goods. The subsidiary's registered office is in Al-Ahsa, Kingdom of Saudi Arabia. The Company has accounted for investment in subsidiary at cost and classified as investment in unconsolidated subsidiary. The assets, liabilities and operations of the subsidiary as of 30 September 2026 and for the period then ended are not material to the Company's financial statements. Management continues to assess the requirement for consolidation of the subsidiary in future reporting periods in accordance with the applicable financial reporting standards.

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES

2.1 Statement of compliance

These condensed interim financial statements have been prepared in accordance with International Accounting Standard IAS 34 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements that are issued by Saudi Organization for Chartered and Professional Accountants ("SOCPA") and should be read in conjunction with the Company's last annual Financial Statements for the year ended 31 December 2025. These do not include all of the information normally required for a complete set of Financial Statements; however, accounting policies and selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since 31 December 2025. The results of the nine-month period ended might not be the indicator of full year results of the Company.

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES (Continued)

2.2 Basis of preparation

These condensed interim financial statements have been prepared on a historical cost basis except for derivative financial instruments, investments at fair value through profit or loss which are measured at fair value and employees' end-of-service benefits obligation which is measured at the present value of the obligations.

2.3 Functional and presentation currency

These condensed interim financial statements are presented in Saudi Riyals (SAR) which is the Company's functional currency. All financial information presented in these condensed interim financial statements have been rounded off to the nearest Saudi Riyals, unless otherwise stated.

2.4 Use of judgements and estimates

In preparing these condensed interim financial statements, management has made judgments and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. The significant judgments made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

3. Material accounting policies

The accounting policies applied in these condensed interim financial statements are the same as those applied in the Company's annual financial statements as at and for the year ended 31 December 2025.

4. NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS

4.1 New and revised standards with no material effect on the financial statements

The following revised IFRSs have been adopted. The application of these revised IFRSs did not have any material impact on the amounts reported for current and prior periods.

- Amendments to the Classification and Measurement of Financial Instruments - Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures, effective for annual periods beginning on or after 1 January 2026.
- Contracts Referencing Nature-dependant Electricity – Amendments to IFRS 9 and IFRS 7, effective for annual periods beginning on or after 1 January 2026.
- Annual improvements to IFRS Accounting Standards – Amendments to: IFRS 1 First-time Adoption of International Financial Reporting Standards, IFRS 7 Financial Instruments: Disclosures and it's accompanying Guidance on implementing IFRS 7, IFRS 9 Financial Instruments, IFRS 10 Consolidated Financial Statements, and IAS 7 Statement of Cash flows, effective for annual periods beginning on or after 1 January 2026.

However, such amendments did not have an impact on the financial statement of the Company.

4.2 New and revised standards issued but not yet effective

The amendments to existing standards that are issued, but not yet effective, up to the date of issuance of the Company's financial statements are disclosed below. The Company intends to adopt these amendments to existing standards, if applicable, when they become effective:

- IFRS 18 Presentation and Disclosure in Financial Statements, effective for annual periods beginning on or after 1 January 2027.
- IFRS 19 Subsidiaries without Public Accountability: Disclosures, effective for annual periods beginning on or after 1 January 2027.
- Sale or Contribution of Assets between an Investor and its Associate or Joint Venture - Amendments to IFRS 10 Consolidated Financial Statements and IAS 28 Investments in Associates and Joint Ventures, effective date to be determined.

The forthcoming amendments listed above are not expected to have a significant or material impact on the Company's financial statements when they become effective except IFRS 18.

4. NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS (Continued)

4.2 New and revised standards issued but not yet effective (Continued)

IFRS 18 Presentation and Disclosure in Financial Statements will replace IAS 1 Presentation of Financial Statements and applies for annual reporting periods beginning on or after 1 January 2027. The Company has not early adopted the new accounting standard in preparing these interim financial statements; however, earlier application is permitted.

a) Structure of the Statement of Profit or Loss

IFRS 18 requires entities to classify all income and expenses into categories in the statement of profit or loss – namely operating, investing, financing, zakat income tax and discontinued operations. Classification of income and expenses depends on the main business activities of an entity. The Company has determined that it does not have a specified main business activity of investing in assets and/or providing financing to customers.

Neither net profit nor net assets will change as a result of the Company's adoption of IFRS 18. The Company will be required to present two newly defined subtotals, which are 'operating profit' and 'profit or loss before financing and income taxes'. However, operating profit subtotal differs from the current operating profit subtotal presented by the Company. Based on the information currently available, the Company expects changes to the current structure of the statement of profit or loss to result from the following:

- Interest income and expenses are generally included in finance income and finance costs under the Company's current accounting policy and are separately presented as finance income and finance costs respectively. IFRS 18 provides specific guidance on the income and expenses to be classified in the investing and financing categories.
- Gains and losses on derivative financial instruments are currently disclosed in the statement of profit or loss and other comprehensive income below the operating profit. The Company has determined that gains or losses on these derivative financial instruments are expected to be classified in the financing categories.
- Share of profit / (loss) of equity-accounted investees is currently presented below net finance costs and above profit before zakat. Income and expenses from equity-accounted investments are always classified in the investing category under IFRS 18. Accordingly, the Company's share of profit of equity-accounted investees will be classified and presented in the investing category.

b) Management-defined performance measures

Management-defined performance measures (MPMs) are subtotals of income and expenses used in public communications outside the financial statements that communicate users management's view of an aspect of the financial performance of the entity as a whole. The Company will be required to disclose specific information about MPMs in a single note in the financial statements.

The Company is in process to determine which public communications should be considered when identifying MPMs. MPMs relate to the same reporting period as the financial statements. Therefore, MPMs disclosed by the Company following adoption of IFRS 18 will be determined based on public communications issued by the Company relating to the 2027 interim reporting period.

c) Principles of aggregation and disaggregation

IFRS 18 provides enhanced principles on how to group information in the financial statements (i.e. the primary financial statements and the notes). It also introduces guidance on labelling and describing items presented in the primary financial statements or disclosed in the notes.

The Company is assessing the grouping of items on the basis of similar and dissimilar characteristics. Based on this assessment, it will present line items in the primary financial statements that provide useful structured summaries and disclose additional information in the note. The Company is also assessing line items currently labelled as 'other' and will use more informative labels.

d) Consequential amendments

IFRS 18 introduces consequential amendments to IAS 7, which require entities to use the newly defined operating profit subtotal as the starting point for the statement of cash flows when presenting operating cash flows under the indirect method. The Company currently uses profit for the year/period as the starting point of the reconciliation to cash flows from operating activities. Certain adjusting items included in the reconciliation will change as a result of the new starting point.

The consequential amendments also provide specific guidance on the classification of interest and dividend cash flows. Cash flows from interest received and dividends paid will continue to be classified as investing activities and financing activities, respectively.

5. PROPERTY AND EQUIPMENT

The movement of property and equipment is as follows:

	30 September 2026	31 December 2025	30 September 2025
	(Unaudited)	(Audited)	(Unaudited)
Carrying value at the beginning of the period /year	**2,364,595,805**	1,894,434,303	1,894,434,303
Additions (note 5.1)	**892,909,770**	557,734,058	406,300,638
Disposals, net of accumulated depreciation	**(4,850,430)**	(2,433,099)	(7,812)
Depreciation for the period /year	**(70,310,897)**	(85,139,457)	(62,047,037)
Carrying value at the end of the period /year (note 5.2)	**3,182,344,248**	2,364,595,805	2,238,680,092

5.1 The additions to property and equipment include capital work-in-progress of SAR 794.37 million (31 December 2025: SAR 436.90 million and 30 September 2025: SAR 319.32 million), primarily related to the Al Khobar and Al Hofuf hospitals. During the period, borrowing costs on various long-term loans were also capitalized, amounting to SAR 40.93 million (31 December 2025: SAR 31 million and 30 September 2025: SAR 19.68 million).

5.2 The carrying value includes construction work-in-progress amounting to SAR 1,421.66 million (31 December 2025: SAR 656.55 million and 30 September 2025: SAR 580.11 million). It represents costs incurred in relation to Al Khobar hospital (expected completion in 2028), Al Hofuf hospital (expected completion in 2027), medical centers and other projects of the Company, which are currently under construction.

6. ACCOUNTS RECEIVABLE

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
Accounts receivable – trade	**803,552,902**	620,900,888
Less: allowance for expected credit losses	**(15,726,585)**	(5,823,876)
	787,826,317	615,077,012
Due from related parties (note 15.2)	**2,441,579**	604,104
	790,267,896	615,681,116

6.1 Following is the movement of allowance for expected credit losses:

	30 September 2026	31 December 2025	30 September 2025
	(Unaudited)	(Audited)	(Unaudited)
Balance at the beginning of the period / year	**5,823,876**	5,141,118	5,141,118
Allowance for expected credit losses during the period / year	**10,257,151**	6,837,151	2,706,203
Doubtful debts written off during the period / year	**(354,442)**	(6,154,393)	(2,269,730)
Balance at the end of the period / year	**15,726,585**	5,823,876	5,577,591

7. INVESTMENT

	Note	**30 September 2026**	31 December 2025
		(Unaudited)	(Audited)
Investment in mutual funds	7.2	**38,820,477**	42,285,006
Investment in sukuk certificates	7.1	**-**	40,000,000
Balance at the end of the period / year		**38,820,477**	82,285,006

7. INVESTMENT (Continued)

7.1 Investment in sukuk certificates

The Company had invested SAR 40 million in 40 Sukuk certificates, each with a nominal value of SAR 1 million. The Sukuk carried a fixed rate of commission payable by the bank quarterly, with the first call date of 3 February 2030.
During the period, the Company sold the Sukuk investment for proceeds of SAR 39.8 million.

7.2 Investment in mutual and murabaha funds

The Company has made the investment in mutual and murabaha funds and measured at fair values using the price quoted from Saudi Stock Exchange (Tadawul). The investment has been classified as a Level 1 fair value hierarchy being determined based on quoted prices in active markets at the period -end.

	30 September 2026	31 December 2025	30 September 2025
	(Unaudited)	(Audited)	(Unaudited)
Balance at the beginning of the period / year	**42,285,006**	-	-
Additions during the period / year	**-**	150,000,000	150,000,000
Redemption during the period / year	**-**	(101,353,058)	(101,353,058)
Realized gain on redemption	**-**	1,353,058	1,353,058
Unrealized loss	**(3,464,529)**	(7,714,994)	(3,162,107)
Net loss	**(3,464,529)**	(6,361,936)	(1,809,049)
Balance at the end of the period	**38,820,477**	42,285,006	46,837,893

8. LONG TERM LOANS

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
Current		
Loans from commercial banks	**42,000,000**	30,730,137
Loans from Ministry of Finance	**2,843,067**	2,843,067
Accrued interest expense	**13,736,464**	4,972,144
	58,579,531	38,545,348
Non- current		
Loans from commercial banks	**1,454,200,913**	659,470,776
Loans from Ministry of Finance	**5,686,131**	8,529,196
Less: deferred income on loan from MoF	**(586,273)**	(804,445)
	1,459,300,771	667,195,527

Loans from Commercial Banks
The Company obtained loan facilities from various local commercial banks. These facilities are subject to commission rates based on Saudi Arabia Interbank Offered Rate "SIBOR" plus an agreed margin.

Loans from Ministry of Finance
In 2010, the Company entered into a loan agreement for SAR 42.6 million with Ministry of Finance to finance the construction of hospital building. The loan is repayable in equal annual instalments of SAR 2.8 million each which commenced from 2015 and will continue up to 2030.

The Company is required to comply with certain covenants under the loan facility agreements mentioned above. A future breach of covenants may lead to renegotiation. The covenants are timely monitored, in case of potential breach, actions are taken by management to ensure compliance.

As of 30 September 2026, there is no non-compliance of loan covenants from banks.

8. LONG TERM LOANS (Continued)

Following are the combined aggregate amounts of future maturities representing principal amounts of the term loans as at:

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
Within one year	**44,843,067**	33,573,204
Later than one year but not later than five years	**854,997,044**	495,903,260
Later than five years	**604,890,000**	172,096,712
	1,504,730,111	701,573,176

9. DERIVATIVE FINANCIAL INSTRUMENTS

The Company enters into derivative financial instruments with various counterparties, principally financial institutions, to manage its exposure to interest rate risk arising from its financing arrangements and are not designated as hedge instruments. These instruments include callable range accrual swaps (floating-to-fixed rate) and interest rate collars (comprising interest rate caps and floors).

Under callable range accrual swaps, the Company exchanges floating-rate interest payments for fixed-rate payments, subject to specified conditions, including range conditions. Interest rate collars are used to limit the Company's exposure to fluctuations in interest rates by establishing a range within which the interest rate is effectively capped and floored.

These derivative financial instruments are classified as financial assets or financial liabilities at fair value through profit or loss (FVTPL). Accordingly, changes in their fair values are recognized in the statement of profit or loss in the period in which they arise.

The notional principal amounts of Callable range accrual swaps is SAR 950 million (31 December 2025: SAR 950 million) and Interest rate collars is SAR 144 million 31 December 2025: SAR 180 million). The fair value of the derivative financial asset is SAR 0.40 million (31 December 2025: SAR 2.08 million) and the fair value of the derivative financial liabilities is SAR 160.09 million (31 December 2025: SAR 57.57 million). The net loss / (gain) arising from changes in fair value of derivative financial instruments recognized in the statement of profit or loss and other comprehensive income amounts to SAR 104.20 million (31 December 2025: (SAR 36.20 million)). The valuation techniques applied include Hull-White 1 Factor model. The models incorporate various inputs including the 3m SAIBOR swaption ATM volatilities, 3M SAIBOR curve to determine the forward rates and discount rates. The fair value measurements are categorized within Level 2 of the fair value hierarchy.

	30 September 2026	31 December 2025	30 September 2025
	(Unaudited)	(Audited)	(Unaudited) (Restated)
Balance at start of period / year	**55,487,742**	91,688,645	91,688,645
Change in fair value	**104,204,121**	(36,200,903)	(46,497,459)
Balance at end of period / year	**159,691,863**	55,487,742	45,191,186
Derivative financial assets – non-current	**401,098**	2,077,976	1,109,079
Derivative financial assets – current	**-**	-	276,984
Derivative financial liabilities – non-current	**136,937,482**	53,056,112	45,748,834
Derivative financial liabilities – current	**23,155,479**	4,509,606	828,415

10. ZAKAT PROVISION

The movement in zakat provision is:

	30 September 2026	31 December 2025	30 September 2025
	(Unaudited)	(Audited)	(Unaudited)
Balance at the beginning of the period / year	**10,577,222**	8,864,912	8,864,912
Charge for the period / year	**4,135,636**	7,977,222	2,627,505
Prior year adjustment	**-**	(3,802,408)	(3,802,408)
	4,135,636	4,174,814	(1,174,903)
Paid during the period / year	**(7,534,161)**	(2,462,504)	(2,462,504)
Balance at the end of the period / year	**7,178,697**	10,577,222	5,227,505

The Company has submitted its zakat returns up to year 2025 and has obtained the required certificates and official receipts. The final assessment for the year 2019 has been received from ZATCA, however, the remaining returns are still under ZATCA review.

11. REVENUE

The Company primarily generates revenue from contract with customers from:

- Services relating to inpatient and outpatient; and
- Sale of pharmaceutical goods.

Disaggregation of revenue
In the following table, revenue from contracts with customers is disaggregated by service lines and timing of revenue recognition.

	For the nine-month period ended 30 September	
	2026	2025
	(Unaudited)	(Unaudited)
Revenue by service lines		
Medical services	**736,581,856**	674,561,568
Pharmaceuticals	**258,800,902**	230,807,745
Rehabilitation	**162,075,116**	122,957,084
	1,157,457,874	1,028,326,397
Timing of revenue recognition		
Medical services and pharmaceuticals sales transferred at a point in time	**587,103,041**	482,883,789
Medical services transferred over time	**570,354,833**	545,442,608
	1,157,457,874	1,028,326,397

Revenue from medical services and rehabilitation is recognized at a point in time as well as over time based on the underlying nature of services provided.

The following table provides information about refund liability from contracts with customers:

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
Refund liability (note 11.1)	**84,766,528**	63,561,645

11. REVENUE (Continued)

11.1 REFUND LIABILITY

Certain contracts provide for discounts comprising retrospective volume discounts granted to insurance companies on attainment of certain admission levels / certain levels of patient visits. The retrospective volume discounts give rise to variable consideration. Variable consideration is recognised as revenue to the extent that it is highly probable that it will not reverse. Discounts are accrued over the course of the period based on the estimates of the level of business expected using single most likely amount method. This is adjusted at the end of the period to reflect actual volumes. Volume discounts are recorded as a reduction in revenue and liabilities are created based on these estimates.

12. OTHER INCOME

	For the nine-month period ended 30 September	
	2026	2025
	(Unaudited)	(Unaudited)
Human Resource Development Fund (HRDF) income	**7,431,166**	9,555,584
Training courses income	**2,321,644**	605,010
Rental income	**1,818,193**	691,993
Gain on disposal of property and equipment	**1,705,330**	45,760
Scientific support income	**511,924**	425,326
Cafeteria income	**-**	55,056
Others	**131,109**	-
	13,919,366	11,378,729

13. FINANCE INCOME

	For the nine-month period ended 30 September	
	2026	2025
	(Unaudited)	(Unaudited)
Income from derivatives	**2,396,791**	-
Income from Sukuks	**1,274,223**	1,653,333
Income from time deposits	**783,216**	6,121,916
	4,454,230	7,775,249

14. CONTINGENT LIABILITIES AND COMMITMENTS

Letter of Guarantees

As of 30 September 2026, the Company's bankers have given letter of guarantees, on behalf of the Company, amounting to SAR 51.5 million (31 December 2025: SAR 27 million) mainly in respect of performance guarantees to customers and others.

Letter of Credits

As of 30 September 2026, the Company's bankers have given letter of credits, on behalf of the Company, amounting to SAR 12.2 million (31 December 2025: SAR 19.51 million).

Capital commitments

As of 30 September 2026, the Company’s capital commitments amounted to SAR 2,053.86 million (31 December 2025: SAR 849.72 million) related to Al Khobar hospital, Al Hofuf hospital, medical centers and other projects of the Company.

15. RELATED PARTY TRANSACTIONS AND BALANCES

Related parties include the Company's ultimate controlling person (Abdulaziz Abdullah AlMoosa), other shareholders, associated companies and their shareholders, key management personnel, Board of Directors, and entities controlled, jointly controlled or significantly influenced by such parties. Terms and conditions of these transactions are approved by the Company's management. The following are the nature and transactions with the related parties during the period and its related balances as at end of the period.

Related Party	Relationship
Abdulaziz bin Abdullah Al Moosa Investment Company	Owned by ultimate controlling person
Specialised Eye Company	Wholly owned subsidiary
Al Moosa College of Health Sciences	Owned by ultimate controlling person
Al Moosa Doors Factory	Owned by ultimate controlling person
Abdulaziz Almoosa Charity Company	Owned by ultimate controlling person

15.1 The following transactions were carried out with related parties during the period / year:

Related Party	Nature	**30 September 2026**	31 December 2025	30 September 2025
		(Unaudited)	(Audited)	(Unaudited)
Al Moosa College of Health Sciences	Services supplied	**2,094,782**	2,073,222	890,787
	Services received	**(2,995,562)**	(2,254,115)	(1,649,273)
Specialised Eye Company	Payment on behalf of subsidiary	**2,249,964**	-	-
Al Moosa Doors Factory	Purchase of goods	**(5,725)**	(197,807)	(197,807)
Abdulaziz Almoosa Charity Company	Services supplied	**321,984**	26,512	16,620
Abdulaziz bin Abdullah Al Moosa Investment Company	Initial public offering cost	**-**	-	17,304,666

15.2 *Due from related parties*

The breakdown of the amounts due from related party is as follows:

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
Specialised Eye Company	**2,249,964**	-
Abdulaziz Almoosa Charity Company	**191,615**	26,512
Al Moosa College of Health Sciences	**-**	577,592
	2,441,579	604,104

Prices and terms of payments for the above transactions are approved by the management. Due from related parties is unsecured in nature and bears no interest. There is no provision held against amount due from related parties.

15.3 *Compensation to key management personnel*

Key management includes the Board of Directors (executive and non-executive) and all members of Company's management. The compensation paid or payable to key management for employee services is shown below:

	For the nine-month period ended 30 September	
	2026	2025
	(Unaudited)	(Unaudited)
Short-term benefits	**7,470,300**	7,899,800
Termination benefits	**492,788**	487,788
	7,963,088	8,387,588

16. EARNINGS PER SHARE

Basic and diluted earnings per share is calculated by dividing the net income for the period attributable to the shareholders of the Company by the weighted average number of outstanding shares during the period. As the Company does not have any dilutive potential shares, the diluted earnings per share is the same as basic earnings per share.

	For the nine-month period ended 30 September	
	2026	2025
	(Unaudited)	(Unaudited) (Restated)
Profit for the period attributable to the shareholders of the Company	**30,298,009**	201,036,582
Weighted average number of outstanding shares during the period	**44,303,580**	44,099,106
Basic and diluted earnings per share	**0.68**	4.56

17. DIVIDENDS

During the period, the Board of Directors, at its meeting held on 11 March 2026, approved a cash dividend of SAR 15.51 million (SAR 0.35 per share) for the quarter ended 31 December 2025 (31 December 2024: 44.3 million). The Board of Directors, at its meeting held on 11 May 2026, approved a cash dividend of SAR 11.08 million (SAR 0.25 per share) for the quarter ended 31 March 2026 (31 March 2025: 11.08 million). Additionally, on 06 August 2026, the Board of Directors approved a cash dividend of SAR 11.08 million (SAR 0.25 per share) for the quarter ended 30 June 2026 (30 June 2025: 15.51 million).

18. FINANCIAL INSTRUMENTS – FAIR VALUE AND RISK MANAGEMENT

The Company's principal financial assets include cash and cash equivalents, accounts receivable, investments and certain other receivables that arise directly from its operations. The Company's principal financial liabilities comprise long-term borrowings, lease liabilities, accounts payable and other payables. The main purpose of these financial liabilities is to finance the Company's operations.

Fair values hierarchy
All financial instruments for which fair value is recognized or disclosed are categorized within the fair value hierarchy, based on the lowest level input that is significant to the fair value measurement as a whole, as follows:
Level 1: Quoted (unadjusted) market prices in active markets for identical assets or liabilities.
Level 2: Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
Level 3: Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognized at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

There were no changes in the Company's valuation processes, valuation techniques, and types of inputs used in the fair value measurements during the period.

18. FINANCIAL INSTRUMENTS – FAIR VALUE AND RISK MANAGEMENT (Continued)

Accounting classifications and fair values

The following table shows the carrying value of financial assets and financial liabilities measured at either amortised cost or fair value.

Particulars	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Financial assets measured at fair value		
Investment (note 7)	**38,820,477**	82,285,006
Derivative financial assets (note 9)	**401,098**	2,077,976
	39,221,575	84,362,982
Financial assets not measured at fair value		
Cash and cash equivalent	**42,000,231**	38,270,406
Accounts receivable (note 6)	**805,994,481**	621,504,992
Other current assets	**2,343,590**	2,124,426
Total financial assets not measured at fair value	**850,338,302**	661,899,824
Total financial assets	**889,559,877**	746,262,806

Particulars	30 September 2026 Carrying value (Unaudited)	31 December 2025 Carrying value (Audited)
Financial liabilities measured at fair value		
Derivative financial instruments (note 9)	**160,092,961**	57,565,718
Financial liabilities not measured at fair value		
Long term loans (note 8)	**1,517,880,302**	705,740,875
Short term borrowings	**-**	20,000,000
Lease liabilities	**85,823,459**	86,757,811
Accounts payable	**332,837,466**	266,129,522
Other current liabilities	**14,427,795**	17,095,174
Total financial liabilities not measured at fair value	**1,950,969,022**	1,095,723,382
Total financial liabilities	**2,111,061,983**	1,153,289,100

Risk management activities

The Company's financial risk management objectives and policies are consistent with those disclosed in the last annual financial statements as at and for the year ended 31 December 2025.

19. SEGMENT REPORTING

Segment reporting is based on the operating (business) segments of the Company. An operating segment is a component of the Company that engages in business activities from which it may earn revenue or incur expenses. An operating segments operating results are reviewed regularly by the chief executive officer of the Company to make the decision about the resources allocated to the segment and assess its performance, and for which discrete financial information is available.

The segment results presented to the Board of Directors include both items directly attributable to each segment and those that can be reasonably allocated. The business segments operate in distinct areas, each facing unique risks and rewards.

19. SEGMENT REPORTING (Continued)

The reported segments are:

- Medical Services - Hospital: Focused on delivering medical care and treatment.
- Rehabilitation Centre: Specializing in rehabilitation-related services.
- Pharmacy: Engaged in the sale of medicines.

	Medical Services Hospital	Rehabilitation Centre	Pharmacy	Total
For the period ended 30 September 2026				
Revenues	**736,581,856**	**162,075,116**	**258,800,902**	**1,157,457,874**
Cost of revenues	**(500,022,148)**	**(114,698,463)**	**(187,679,523)**	**(802,400,134)**
Gross profit	**236,559,708**	**47,376,653**	**71,121,379**	**355,057,740**
General and administrative expenses	**(123,772,937)**	**(31,249,917)**	**(27,092,427)**	**(182,115,281)**
Selling and marketing expenses	**(12,642,677)**	**(3,950,836)**	**(3,160,669)**	**(19,754,182)**
Impairment loss on accounts receivable	**(6,520,903)**	**(1,434,839)**	**(2,301,409)**	**(10,257,151)**
Other income	**11,561,952**	**1,787,821**	**569,593**	**13,919,366**
Operating profit	**105,185,143**	**12,528,882**	**39,136,467**	**156,850,492**
Loss on investments	**(3,464,529)**	**-**	**-**	**(3,464,529)**
Loss on derivative financial instruments	**(104,204,121)**	**-**	**-**	**(104,204,121)**
Finance cost	**(7,335,538)**	**(12,004,160)**	**(497,802)**	**(19,837,500)**
Finance income	**4,454,230**	**-**	**-**	**4,454,230**
Share of profit from equity accounted investee	**635,073**	**-**	**-**	**635,073**
(Loss) / profit before zakat	**(4,729,742)**	**524,722**	**38,638,665**	**34,433,645**
Zakat expense for the period	**(2,629,198)**	**(578,520)**	**(927,918)**	**(4,135,636)**
(Loss) / profit for the period	**(7,358,940)**	**(53,798)**	**37,710,747**	**30,298,009**
Other comprehensive income for the period	**2,356,975**	**569,793**	**181,534**	**3,108,302**
Total comprehensive (loss) / income for the period	**(5,001,965)**	**515,995**	**37,892,281**	**33,406,311**

19. SEGMENT REPORTING (Continued)

	Medical Services Hospital	Rehabilitation Centre	Pharmacy	Total
For the period ended 30 September 2025		(Restated)		
Revenues	674,561,568	122,957,084	230,807,745	1,028,326,397
Cost of revenues	(450,441,578)	(89,385,903)	(160,189,033)	(700,016,514)
Gross profit	224,119,990	33,571,181	70,618,712	328,309,883
General and administrative expenses	(101,583,460)	(34,871,934)	(15,161,711)	(151,617,105)
Selling and marketing expenses	(12,480,666)	(7,904,421)	(416,022)	(20,801,109)
Impairment loss on accounts receivable	(1,775,215)	(323,581)	(607,407)	(2,706,203)
Other income, net	9,318,450	1,602,439	457,840	11,378,729
Other expenses – IPO related cost	(1,141,632)	-	-	(1,141,632)
Operating profit / (loss)	116,457,467	(7,926,316)	54,891,412	163,422,563
Other expenses – loss on investment	(1,808,836)	-	-	(1,808,836)
Gain on derivative financial instruments	46,497,458	-	-	46,497,458
Share of profit from equity accounted investee	355,127	-	-	355,127
Finance income	7,775,249	-		7,775,249
Finance cost	(3,275,976)	(13,103,906)	-	(16,379,882)
Profit / (loss) before zakat	166,000,489	(21,030,222)	54,891,412	199,861,679
Zakat	770,713	140,483	263,707	1,174,903
Profit/ (loss) for the period	166,771,202	(20,889,739)	55,155,119	201,036,582
Other comprehensive income for the period	1,959,385	434,997	152,375	2,546,757
Total comprehensive income / (loss) for the period	168,730,587	(20,454,742)	55,307,494	203,583,339
As at 30 September 2026				
Segment assets	**3,370,201,698**	**856,269,060**	**58,744,813**	**4,285,215,571**
Segment liabilities	**1,838,922,804**	**425,549,763**	**100,769,552**	**2,365,242,119**
As at 31 December 2025				
Segment assets	2,421,060,378	843,245,734	48,795,137	3,313,101,249
Segment liabilities	807,668,132	498,487,817	82,720,116	1,388,876,065

All of the Company's operating assets and principal activities are located in the Kingdom of Saudi Arabia. The accounting policies of the reportable segments are the same as the Company's accounting policies. Segment profit represents the profit earned by each segment after allocation of the central administration costs including directors' salaries, non-operating gains in respect of financial instruments and finance costs. This is the measure reported to the Company's Board of Directors.

20. RESTATEMENT OF PRIOR PERIOD

As disclosed in the Company's annual financial statements for the year ended 31 December 2025, the derivative financial instruments were not recognised at fair value, with changes in fair value recognised in the statement of profit or loss, as required by IFRS 9 Financial Instruments. Instead, these instruments were carried at amounts reflecting the interest payable under the arrangements as at the reporting dates.

As a result, the fair value of these financial assets and/or liabilities and the resulting gains/ (losses) were not recognised in the financial statements for the year ended 31 December 2024 and earlier periods. In accordance with IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors, the error has been corrected retrospectively by restating the affected financial statement line items for the prior periods.

The effects of these adjustments have been reflected in the Company's condensed interim financial statements as follows:

Statement of profit or loss and other comprehensive income	Impact of correction of error		
For the nine-month period ended 30 September 2025	As previously reported	Adjustment	As restated
Gain on derivative financial instruments	-	46,497,458	46,497,458
Profit for the period	154,539,124	46,497,458	201,036,582
Total comprehensive income for the period	157,085,881	46,497,458	203,583,339
For the three-month period ended 30 September 2025			
Gain on derivative financial instruments	-	14,205,368	14,205,368
Profit for the period	51,637,966	14,205,368	65,843,334
Total comprehensive income for the period	52,178,963	14,205,368	66,384,331

The change did not have an impact on OCI for the period or the Company's operating, investing and financing cash flows. Basic and diluted earnings per share for the period ended 30 September 2025 have also been restated. The amount of the correction for basic and diluted earnings per share was an increase of SAR 1.06 per share.

21. SUBSEQUENT EVENTS

Due to the recent geopolitical tensions, the Company continues to monitor their potential impact on Saudi Arabia given that the Company's operations are conducted mainly in the Kingdom of Saudi Arabia ("KSA"). While the situation remains evolving, the Company maintains a robust operational framework to manage associated risks. These developments have not had a material impact on the Company's condensed interim financial statements for the period ended 30 September 2026; however, given the evolving nature of the conflict, the potential long-term impact on the Company's business will continue to be assessed on future reporting dates.

On 04 November 2026, the Board of Directors, in their meeting, declared a cash dividend of SAR 11.08 million, equivalent to SAR 0.25 per share for the third quarter ended 30 September 2026 (30 September 2025: 15.51 million).

Except for the above there are no other significant subsequent events have occurred from the date of these condensed interim financial statements to the date of approval of these condensed interim financial statements, that would require adjustments or disclosure in these condensed interim financial statements of the Company.

22. APPROVAL OF THE CONDENSED INTERIM FINANCIAL STATEMENTS

These condensed interim financial statements were authorized for issue by the Board of Directors and approved on 24 Jumada Al-Awwal 1448H, corresponding to 04 November 2026G.